MICA: Applying innovative technologies to improve benefit-risk ratio of drugs: developing a national resource underpinned by the MRC Centre for CDSS
Lead Research Organisation:
University of Liverpool
Department Name: Institute of Translational Medicine
Abstract
The use of drugs as medicines has made an enormous contribution to human health with the drug discovery process being directed to most aspects of human disease. However, all drugs are associated with variability in response: that is some patients do not respond to drugs, while others develop side effects or adverse drug reactions (ADRs). This may be related to patient factors (genetic or environmental) or differences in their disease. The overall burden caused by differences in the way patients respond to drugs is large to both the NHS and Industry. For example, with ADRs, we have shown that at least 6.5% of all adult admissions to hospitals are due to ADRs and that approximately 15% of inpatients suffer an ADR during hospitalisation. Extrapolated nationally, ADRs are thought to cost the NHS in England in excess of £637 million annually, or approximately £5000 per hospital bed per year. This is a conservative estimate and is likely to be much higher. Our findings in the UK have been replicated in many countries showing that ADRs are a global health issue.
Our application focuses on the MRC Centre for Drug Safety Science (CDSS) which has an international reputation. The patient is at the centre of the work we undertake. We have developed an infrastructure that allows pre-clinical and clinical scientists to work side-by-side using cutting-edge technologies to analyse well-defined clinical samples. In this application, we request state-of-the-art technologies to build upon this infrastructure and produce a step-change in the area of stratified medicine - that is, to identify the best treatments for patients based on profiling their disease, genetic and environmental factors. Our aim is to develop a comprehensive resource, based on our existing expertise and experience and the technology platforms, to allow for assessment of how individuals vary in drug responses, how diseases differ between individuals, and how this relates to variation in clinical outcomes. We will do this through investigation of different "experimental" systems ranging from single cells in test-tubes to experimental studies in man, to careful clinical observation of patients in clinical settings. This will facilitate translation of findings in the laboratory to clinical care (bench to bedside), but importantly lessons learnt in clinical settings will also be investigated further in the laboratories (bedside to bench), so that we can learn more about disease processes.
Our application focuses on the MRC Centre for Drug Safety Science (CDSS) which has an international reputation. The patient is at the centre of the work we undertake. We have developed an infrastructure that allows pre-clinical and clinical scientists to work side-by-side using cutting-edge technologies to analyse well-defined clinical samples. In this application, we request state-of-the-art technologies to build upon this infrastructure and produce a step-change in the area of stratified medicine - that is, to identify the best treatments for patients based on profiling their disease, genetic and environmental factors. Our aim is to develop a comprehensive resource, based on our existing expertise and experience and the technology platforms, to allow for assessment of how individuals vary in drug responses, how diseases differ between individuals, and how this relates to variation in clinical outcomes. We will do this through investigation of different "experimental" systems ranging from single cells in test-tubes to experimental studies in man, to careful clinical observation of patients in clinical settings. This will facilitate translation of findings in the laboratory to clinical care (bench to bedside), but importantly lessons learnt in clinical settings will also be investigated further in the laboratories (bedside to bench), so that we can learn more about disease processes.
Technical Summary
Our research vision aims to identify clinically relevant problems (using a variety of patient recruitment strategies including electronic health record databases such as CPRD and the infrastructure being developed through the Farr Institutes), and use the requested state-of-the-art technologies (single cell genomics, metabolomics, proteomics, mass cytometry, and computing infrastructure) to identify mechanism-based disease strata to improve the benefit-risk ratio of current and new medicines, for the benefit of patients, industry and regulators. The application builds on the existing infrastructure of the MRC Centre for Drug Safety Science (CDSS) at the University of Liverpool (UoL).
The overarching aim is to optimize 'systems pharmacology' approaches applying scientific innovation that will produce physiologically and mechanistically-based biomarkers, which will tailor drug treatments, prevent the development of more serious ADRs, identify new treatment strategies, and define novel disease mechanisms and pathways. By using drugs as tools, we will not only uncover the mechanisms by which drugs act in the body (in terms of efficacy and toxicity), but also uncover novel pathways of the disease mechanisms (both for diseases for which the drugs are used, but also for unrelated diseases where an ADR acts as a mimic for a disease). The combination of the two provides a powerful platform to catalyse short-, medium- and long-term innovation in stratified medicine, and will ultimately improve clinical outcomes of disease, reduce iatrogenic morbidities, reduce hospital admissions from drug- and non-drug induced disease, and improve cost-effectiveness of therapy.
The overarching aim is to optimize 'systems pharmacology' approaches applying scientific innovation that will produce physiologically and mechanistically-based biomarkers, which will tailor drug treatments, prevent the development of more serious ADRs, identify new treatment strategies, and define novel disease mechanisms and pathways. By using drugs as tools, we will not only uncover the mechanisms by which drugs act in the body (in terms of efficacy and toxicity), but also uncover novel pathways of the disease mechanisms (both for diseases for which the drugs are used, but also for unrelated diseases where an ADR acts as a mimic for a disease). The combination of the two provides a powerful platform to catalyse short-, medium- and long-term innovation in stratified medicine, and will ultimately improve clinical outcomes of disease, reduce iatrogenic morbidities, reduce hospital admissions from drug- and non-drug induced disease, and improve cost-effectiveness of therapy.
Planned Impact
The beneficiaries from our research and the requested technologies will be:
1. Academia
Publishing our research in high-impact journals will ensure that the science-base grows in the mechanism-based understanding of why drug response varies between individuals.
The technologies will further our aim to bring together diverse groups of experts (those with and without experience in drug safety science and stratified medicine).in order to enhance our specific research programmes.
The new technologies will enhance the standing of CDSS as a national and international resource, with collaborators benefitting from access to our clinical samples, access to our cross-cutting technologies, and/or access to our intellectual expertise.
The technologies will further enhance the strong training element of the Centre and Faculty ensuring that non-clinical and clinical academic capacity in drug safety science, stratified medicine, 'omics technologies and systems pharmacology is enhanced. Such comprehensive training will produce 'rounded' scientists with sought-after skill-sets who will make a valuable and practical contribution to the continued growth of this cross-disciplinary medical research activity in the UK.
2. Health Service providers
The information gained from electronic health records will be used to enhance our understanding of variability in drug response
Knowledge gained from our research will lead to changes to drug labels, and clinical guidelines, and thereby more effective prescribing.
Our research will inform prognostic and diagnostic testing strategies that will lead to safer and more cost-effective personalisation of therapies
Scientific outputs will ultimately reduce variability in drug response and their associated financial burden, and improve the benefit-risk ratio of medicines
Continued training will increase the capacity in Clinical Pharmacology and Therapeutics and Translational Medicine in the UK.
3. Pharmaceutical Industry
Scientists from the pharmaceutical industry will continue to use our resources as a focal point for non-competitive research. The technology platforms will further enhance Industry collaborations with the Centre.
Workshops run by the CDSS will incorporate the applications of these technologies which will enhance collaborative links (not necessarily with Centre scientists) that drive novel scientific plans.
Scientific outputs from the CDSS, the Faculty in Liverpool and its collaborators will be used to develop drugs with better benefit:risk profiles
4. Diagnostics Sector
Advances in mechanistic understanding of ADRs and variability in drug response more generally will open up new opportunities for the development of diagnostic and prognostic testing strategies that can be commercialised by the diagnostics sector leading to an improvement in the benefit:risk of drugs
The availability of the technologies will enhance interactions with SMEs especially within the diagnostics sector
5. Regulatory Authorities
Regulatory scientists will input into and gain benefit from the activities of the CDSS and its associated technologies
CDSS scientists will continue to provide expertise to various advisory committees of the MHRA and EMA.
Scientific outputs from the Centre and Faculty enhance the ability of drug regulators to include the relevant information in drug labels. This will thereby contribute towards better evidence-based policy making at a global level.
6. Patients and the General Public
By feeding knowledge and scientific advances through to other stakeholder groups, we will ultimately improve the benefit-risk ratio of drugs. These advances will have a major impact on enhancement of the clinical care of patients thereby leading to an improvement in quality of life.
The general public retains a great deal of interest in all matters relating to drugs and healthcare, and our work will educate the public in their perception of risks and benefits associated with medicines.
1. Academia
Publishing our research in high-impact journals will ensure that the science-base grows in the mechanism-based understanding of why drug response varies between individuals.
The technologies will further our aim to bring together diverse groups of experts (those with and without experience in drug safety science and stratified medicine).in order to enhance our specific research programmes.
The new technologies will enhance the standing of CDSS as a national and international resource, with collaborators benefitting from access to our clinical samples, access to our cross-cutting technologies, and/or access to our intellectual expertise.
The technologies will further enhance the strong training element of the Centre and Faculty ensuring that non-clinical and clinical academic capacity in drug safety science, stratified medicine, 'omics technologies and systems pharmacology is enhanced. Such comprehensive training will produce 'rounded' scientists with sought-after skill-sets who will make a valuable and practical contribution to the continued growth of this cross-disciplinary medical research activity in the UK.
2. Health Service providers
The information gained from electronic health records will be used to enhance our understanding of variability in drug response
Knowledge gained from our research will lead to changes to drug labels, and clinical guidelines, and thereby more effective prescribing.
Our research will inform prognostic and diagnostic testing strategies that will lead to safer and more cost-effective personalisation of therapies
Scientific outputs will ultimately reduce variability in drug response and their associated financial burden, and improve the benefit-risk ratio of medicines
Continued training will increase the capacity in Clinical Pharmacology and Therapeutics and Translational Medicine in the UK.
3. Pharmaceutical Industry
Scientists from the pharmaceutical industry will continue to use our resources as a focal point for non-competitive research. The technology platforms will further enhance Industry collaborations with the Centre.
Workshops run by the CDSS will incorporate the applications of these technologies which will enhance collaborative links (not necessarily with Centre scientists) that drive novel scientific plans.
Scientific outputs from the CDSS, the Faculty in Liverpool and its collaborators will be used to develop drugs with better benefit:risk profiles
4. Diagnostics Sector
Advances in mechanistic understanding of ADRs and variability in drug response more generally will open up new opportunities for the development of diagnostic and prognostic testing strategies that can be commercialised by the diagnostics sector leading to an improvement in the benefit:risk of drugs
The availability of the technologies will enhance interactions with SMEs especially within the diagnostics sector
5. Regulatory Authorities
Regulatory scientists will input into and gain benefit from the activities of the CDSS and its associated technologies
CDSS scientists will continue to provide expertise to various advisory committees of the MHRA and EMA.
Scientific outputs from the Centre and Faculty enhance the ability of drug regulators to include the relevant information in drug labels. This will thereby contribute towards better evidence-based policy making at a global level.
6. Patients and the General Public
By feeding knowledge and scientific advances through to other stakeholder groups, we will ultimately improve the benefit-risk ratio of drugs. These advances will have a major impact on enhancement of the clinical care of patients thereby leading to an improvement in quality of life.
The general public retains a great deal of interest in all matters relating to drugs and healthcare, and our work will educate the public in their perception of risks and benefits associated with medicines.
Organisations
- University of Liverpool (Lead Research Organisation)
- UNIVERSITY OF OXFORD (Collaboration)
- University of Manchester (Collaboration)
- University College London (Collaboration)
- Newcastle University (Collaboration)
- UNIVERSITY OF BIRMINGHAM (Collaboration)
- Illumina Inc. (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- SCIEX (Project Partner)
- Avacta (United Kingdom) (Project Partner)
Publications
Al-Mutawa YK
(2018)
Effects of hypoxic preconditioning on neuroblastoma tumour oxygenation and metabolic signature in a chick embryo model.
in Bioscience reports
Anderson JR
(2020)
Ex Vivo Equine Cartilage Explant Osteoarthritis Model: A Metabolomics and Proteomics Study.
in Journal of proteome research
Anderson JR
(2018)
Synovial Fluid Metabolites Differentiate between Septic and Nonseptic Joint Pathologies.
in Journal of proteome research
Anderson JR
(2018)
1H NMR Metabolomics Identifies Underlying Inflammatory Pathology in Osteoarthritis and Rheumatoid Arthritis Synovial Joints.
in Journal of proteome research
Anderson JR
(2020)
Optimization of Synovial Fluid Collection and Processing for NMR Metabolomics and LC-MS/MS Proteomics.
in Journal of proteome research
Barker E
(2024)
Proximity labelling reveals effects of disease-causing mutation on the DNAJC5/cysteine string protein a interactome.
in The Biochemical journal
Bennett R
(2017)
DOSCATs: Double standards for protein quantification
in Scientific Reports
Chapman EA
(2019)
Caught in a Trap? Proteomic Analysis of Neutrophil Extracellular Traps in Rheumatoid Arthritis and Systemic Lupus Erythematosus.
in Frontiers in immunology
Chokesuwattanaskul S
(2022)
Metabolic Profiling of Rheumatoid Arthritis Neutrophils Reveals Altered Energy Metabolism That Is Not Affected by JAK Inhibition.
in Metabolites
Chokesuwattanaskul S
(2018)
A robust intracellular metabolite extraction protocol for human neutrophil metabolic profiling.
in PloS one
Clarke K
(2017)
The Role of Eif6 in Skeletal Muscle Homeostasis Revealed by Endurance Training Co-expression Networks.
in Cell reports
Colquhoun C
(2017)
Controlling the network type in self-assembled dipeptide hydrogels.
in Soft matter
Derricott H
(2019)
Developing a 3D intestinal epithelium model for livestock species.
in Cell and tissue research
Duckworth AD
(2019)
Multiplexed profiling of RNA and protein expression signatures in individual cells using flow or mass cytometry.
in Nature protocols
Figueiredo CR
(2020)
Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.
in The Journal of pathology
Gaskell H
(2016)
Characterization of a functional C3A liver spheroid model.
in Toxicology research
Gillan V
(2019)
Characterisation of infection associated microRNA and protein cargo in extracellular vesicles of Theileria annulata infected leukocytes.
in Cellular microbiology
Graham RJTY
(2020)
Metabolomic analysis of synovial fluid from Thoroughbred racehorses diagnosed with palmar osteochondral disease using magnetic resonance imaging.
in Equine veterinary journal
Grauslys A
(2020)
Title NMR-based metabolic profiling provides diagnostic and prognostic information in critically ill children with suspected infection.
in Scientific reports
Gupta Juhi
(2021)
Identification of early pregnancy metabolomic biomarkers of women at high-risk of preterm birth using NMR and mGWAS
in BRITISH JOURNAL OF PHARMACOLOGY
Gómez-Baena G
(2017)
Quantitative Proteomics of Cerebrospinal Fluid in Paediatric Pneumococcal Meningitis.
in Scientific reports
Hammond DE
(2018)
Stable Isotope Dynamic Labeling of Secretomes (SIDLS) Identifies Authentic Secretory Proteins Released by Cancer and Stromal Cells.
in Molecular & cellular proteomics : MCP
Held M
(2018)
Ex vivo live cell tracking in kidney organoids using light sheet fluorescence microscopy.
in PloS one
Hetmanski JHR
(2019)
Membrane Tension Orchestrates Rear Retraction in Matrix-Directed Cell Migration.
in Developmental cell
Lee KJ
(2019)
Identification and Characterization of Canine Ligament Progenitor Cells and Their Extracellular Matrix Niche.
in Journal of proteome research
Liu X
(2017)
Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus.
in Genome biology
Luu L
(2015)
Dynamic two-photon imaging of the immune response to Toxoplasma gondii infection.
in Parasite immunology
Luu L
(2019)
An Open-Format Enteroid Culture System for Interrogation of Interactions Between Toxoplasma gondii and the Intestinal Epithelium.
in Frontiers in cellular and infection microbiology
MacDonald E
(2018)
HRS-WASH axis governs actin-mediated endosomal recycling and cell invasion.
in The Journal of cell biology
Margaret Phelan M
(2016)
NMR Metabolomics: A Comparison of the Suitability of Various Commonly used National Health Service Blood Collection Tubes
in Current Metabolomics
Mehanna YA
(2022)
Study on the Influence of Polymer/Particle Properties on the Resilience of Superhydrophobic Coatings.
in ACS omega
Moosa MS
(2023)
Analysis of serum microRNA-122 in a randomized controlled trial of N-acetylcysteine for treatment of antituberculosis drug-induced liver injury.
in British journal of clinical pharmacology
Neves LX
(2020)
Quantitative Proteomics of Enriched Esophageal and Gut Tissues from the Human Blood Fluke Schistosoma mansoni Pinpoints Secreted Proteins for Vaccine Development.
in Journal of proteome research
Phelan MM
(2017)
Using an NMR metabolomics approach to investigate the pathogenicity of amyloid-beta and alpha-synuclein.
in Metabolomics : Official journal of the Metabolomic Society
Schnauß J
(2021)
Cells in Slow Motion: Apparent Undercooling Increases Glassy Behavior at Physiological Temperatures.
in Advanced materials (Deerfield Beach, Fla.)
Schofield A
(2021)
Systems analysis of miRNA biomarkers to inform drug safety
in Archives of Toxicology
Sindrewicz P
(2019)
Intrinsic tryptophan fluorescence spectroscopy reliably determines galectin-ligand interactions.
in Scientific reports
Sindrewicz P
(2020)
Interaction with the heparin-derived binding inhibitors destabilizes galectin-3 protein structure.
in Biochemical and biophysical research communications
Sorzabal-Bellido I
(2022)
Effect of Local Topography on Cell Division of Staphylococcus spp.
in Nanomaterials (Basel, Switzerland)
Spencer C
(2018)
Characterisation of Anopheles gambiae heme oxygenase and metalloporphyrin feeding suggests a potential role in reproduction
in Insect Biochemistry and Molecular Biology
Sun Y
(2016)
Light Modulates the Biosynthesis and Organization of Cyanobacterial Carbon Fixation Machinery through Photosynthetic Electron Flow.
in Plant physiology
Takemori N
(2017)
MEERCAT: Multiplexed Efficient Cell Free Expression of Recombinant QconCATs For Large Scale Absolute Proteome Quantification
in Molecular & Cellular Proteomics
Torpey J
(2020)
Cyclophilin D binds to the acidic C-terminus region of a-Synuclein and affects its aggregation characteristics.
in Scientific reports
Tsuchiya Y
(2020)
Covalent Aurora A regulation by the metabolic integrator coenzyme A.
in Redox biology
Turner RM
(2020)
Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention.
in British journal of clinical pharmacology
Turner RM
(2020)
A Genome-wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites.
in Clinical pharmacology and therapeutics
Description | 3 year project grant |
Amount | £217,307 (GBP) |
Funding ID | CRR1179 |
Organisation | North West Cancer Research (NWCR) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2019 |
End | 03/2022 |
Description | 3DBioNet: an integrated technological platform for 3D micro-tissues |
Amount | £626,046 (GBP) |
Funding ID | MR/R025762/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2018 |
End | 02/2022 |
Description | A Dragonfly multimodal fast imaging platform with SRRF-stream (Super-Resolution Radial Fluctuation) in the Liverpool Centre for Cell Imaging (CCI) |
Amount | £450,000 (GBP) |
Funding ID | BB/R01390X/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 04/2018 |
End | 04/2019 |
Description | CRUK Programme Foundation Award |
Amount | £633,274 (GBP) |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2018 |
End | 05/2023 |
Description | Clinical Scholarship |
Amount | £116,459 (GBP) |
Funding ID | G1015 |
Organisation | Horse Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2015 |
End | 08/2018 |
Description | Developing an ECODB web-service to store and analyse any type of omics data - awarded to Philipp Antczak |
Amount | £16,744 (GBP) |
Organisation | Science and Technologies Facilities Council (STFC) |
Sector | Public |
Country | United Kingdom |
Start | 08/2016 |
End | 03/2017 |
Description | Development of New Mathematical Sciences for Healthcare Technologies |
Amount | £6,200,000 (GBP) |
Funding ID | EP/N014499/1 |
Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
Sector | Public |
Country | United Kingdom |
Start | 12/2015 |
End | 11/2019 |
Description | Development of the chick embryo as a replacement for rodent models of tumour metastasis |
Amount | £240,000 (GBP) |
Funding ID | NC/R001324/1 |
Organisation | National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 02/2021 |
Description | DiMEN MRC DTP studentship |
Amount | £75,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2016 |
End | 03/2019 |
Description | Evaluation of novel combination drug protocols for neuroblastoma using advanced imaging in a chick embryo model |
Amount | £117,000 (GBP) |
Organisation | North West Cancer Research (NWCR) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2018 |
End | 01/2020 |
Description | In Vitro Organ Imaging Device (IV-OID) with integrated Biosensing and Real-Time Imaging Capability: Proof-of-Principle using a Human Placental Model |
Amount | £150,594 (GBP) |
Funding ID | BB/T012056/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 05/2021 |
End | 08/2022 |
Description | International Travel Award Scheme |
Amount | £3,100 (GBP) |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2017 |
End | 12/2017 |
Description | John Goldman Fellowship Award |
Amount | £124,798 (GBP) |
Organisation | Leuka |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2018 |
End | 09/2021 |
Description | Knowledge Transfer Partnership |
Amount | £110,000 (GBP) |
Organisation | Innovate UK |
Sector | Public |
Country | United Kingdom |
Start | 02/2018 |
End | 01/2020 |
Description | NWCR project grant |
Amount | £195,289 (GBP) |
Organisation | North West Cancer Research (NWCR) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2016 |
End | 08/2019 |
Description | NWCRF studentship - Establishment and characterization of a novel pre-clinical animal model to study metastatic recurrence |
Amount | £85,000 (GBP) |
Organisation | North West Cancer Research (NWCR) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2015 |
End | 09/2018 |
Description | North West Cancer Research Development Fund |
Amount | £8,500 (GBP) |
Organisation | North West Cancer Research (NWCR) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2017 |
End | 07/2018 |
Description | Pfizer Aspire Europe |
Amount | £43,866 (GBP) |
Organisation | Pfizer Inc |
Sector | Private |
Country | United States |
Start | 09/2016 |
End | 06/2017 |
Description | Project Grant |
Amount | £443,059 (GBP) |
Funding ID | BB/P001912/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2016 |
End | 09/2019 |
Description | Project grant |
Amount | £44,000 (GBP) |
Organisation | The Kay Kendall Leukaemia Fund |
Sector | Academic/University |
Country | United Kingdom |
Start | 05/2018 |
End | 12/2019 |
Description | Research Fellowship |
Amount | £431,861 (GBP) |
Organisation | Versus Arthritis |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2017 |
End | 05/2022 |
Description | TRDF |
Amount | £43,000 (GBP) |
Funding ID | BB/M020282/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 11/2015 |
End | 10/2016 |
Description | The North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics - fellowship awarded to Dr Anna Olsson-Brown |
Amount | £190,885 (GBP) |
Funding ID | MR/N025989/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 11/2016 |
End | 10/2019 |
Description | clinical-academic fellowship |
Amount | £50,000 (GBP) |
Organisation | British Association of Paediatric Surgeons |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2017 |
End | 12/2017 |
Title | Zegami |
Description | A front-end visualisation platform for querying and interrogating imaging datasets. |
Type Of Material | Improvements to research infrastructure |
Year Produced | 2016 |
Provided To Others? | Yes |
Impact | We have implemented a zegami server to act as a front-end to our public-facing OMERO gallery. This platform allows for the easy visualisation and interrogation of large imaging datasets and so provides an added layer of functionality. Several projects have utilised this system for Open-Data research projects, for an example see: https://doi.org/10.14293/s2199-1006.1.sor-chem.az1mju.v2 and corresponding data available at http://zegami.liv.ac.uk/2016-sf.html |
URL | http://zegami.liv.ac.uk |
Description | CyTof procurement |
Organisation | Newcastle University |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Professor Rob Beynon negotiated with Fluidigm on behalf of all partners who received funds via the MRC Clinical Research Infrastructure award to purchase mass cytometers. The negotiations resulted in a common discounted pricing structure, elevated service provision, and costs towards user-group network meetings. |
Collaborator Contribution | Supporting Professor Beynon where necessary and appropriate |
Impact | Favourable cost reductions for all partners during procurement of seven individual CyTOF machines. |
Start Year | 2015 |
Description | CyTof procurement |
Organisation | University College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Professor Rob Beynon negotiated with Fluidigm on behalf of all partners who received funds via the MRC Clinical Research Infrastructure award to purchase mass cytometers. The negotiations resulted in a common discounted pricing structure, elevated service provision, and costs towards user-group network meetings. |
Collaborator Contribution | Supporting Professor Beynon where necessary and appropriate |
Impact | Favourable cost reductions for all partners during procurement of seven individual CyTOF machines. |
Start Year | 2015 |
Description | CyTof procurement |
Organisation | University of Birmingham |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Professor Rob Beynon negotiated with Fluidigm on behalf of all partners who received funds via the MRC Clinical Research Infrastructure award to purchase mass cytometers. The negotiations resulted in a common discounted pricing structure, elevated service provision, and costs towards user-group network meetings. |
Collaborator Contribution | Supporting Professor Beynon where necessary and appropriate |
Impact | Favourable cost reductions for all partners during procurement of seven individual CyTOF machines. |
Start Year | 2015 |
Description | CyTof procurement |
Organisation | University of Cambridge |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Professor Rob Beynon negotiated with Fluidigm on behalf of all partners who received funds via the MRC Clinical Research Infrastructure award to purchase mass cytometers. The negotiations resulted in a common discounted pricing structure, elevated service provision, and costs towards user-group network meetings. |
Collaborator Contribution | Supporting Professor Beynon where necessary and appropriate |
Impact | Favourable cost reductions for all partners during procurement of seven individual CyTOF machines. |
Start Year | 2015 |
Description | CyTof procurement |
Organisation | University of Manchester |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Professor Rob Beynon negotiated with Fluidigm on behalf of all partners who received funds via the MRC Clinical Research Infrastructure award to purchase mass cytometers. The negotiations resulted in a common discounted pricing structure, elevated service provision, and costs towards user-group network meetings. |
Collaborator Contribution | Supporting Professor Beynon where necessary and appropriate |
Impact | Favourable cost reductions for all partners during procurement of seven individual CyTOF machines. |
Start Year | 2015 |
Description | CyTof procurement |
Organisation | University of Oxford |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Professor Rob Beynon negotiated with Fluidigm on behalf of all partners who received funds via the MRC Clinical Research Infrastructure award to purchase mass cytometers. The negotiations resulted in a common discounted pricing structure, elevated service provision, and costs towards user-group network meetings. |
Collaborator Contribution | Supporting Professor Beynon where necessary and appropriate |
Impact | Favourable cost reductions for all partners during procurement of seven individual CyTOF machines. |
Start Year | 2015 |
Description | Partnership with Illumina for provision of the NextBio Clinical tool |
Organisation | Illumina Inc. |
Department | Illumina |
Country | United Kingdom |
Sector | Private |
PI Contribution | We have provided complex data-sets (genomic, transcriptomic, proteomic) to Illumina and asked for specific functionality in the NextBio Clinical system. |
Collaborator Contribution | Illumina have provided training in NextBio Clinical and hae been working to try to integrate different deata types (transcriptomic, proteomic) into the software tool. |
Impact | None yet |
Start Year | 2016 |
Description | "Meet The Scientist" exhbit at the World Museum |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Our exhibit was entitled: "Seeing inside cells". More than 300 visitors stopped at our exhibit and learned about cells, and how we can use microscopy to understand how they function. Children have visualised cells using a fluorescent microscope. |
Year(s) Of Engagement Activity | 2015 |
URL | https://www.liverpool.ac.uk/health-and-life-sciences/meet-the-scientists/21-november/ |
Description | Health is Wealth conference Liverpool Jan 2015 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Health professionals |
Results and Impact | The purpose to highlight the development, progress and outputs of academic-industrial partnerships in early clinical translation. The purpose of the workshop is to highlight the development, progress and outputs of academic-industrial partnerships in early clinical translation. |
Year(s) Of Engagement Activity | 2015 |
Description | Hosting Lower 6th form summer students via the Nuffield scheme |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | The Centre for Cell imaging has hosted 2 6th form students for 4 weeks as part of the Nuffield Foundation scheme |
Year(s) Of Engagement Activity | 2017 |
Description | Image Analysis Blog |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | A blog, outreach and teaching resource based around the work done by Dave Mason, the CCI BioImage Analyst. The tutorials and educational material largely focuses on Open Source and Open Access tools such that others can apply the methods and techniques to their own quantification. This platform also provides a route to engage with the wider community through comments and interactions on-site and via other social media platforms (IE twitter). |
Year(s) Of Engagement Activity | 2015,2016,2017 |
URL | http://postaquisition.wordpress.com |
Description | Imaging workshop |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | More than 50 attendees participate to the yearly workshop organised by the Centre for Cell imaging. it provides training and awareness of new imaging technologies to group leaders, members of staff and students from the University of Liverpool, other Universities and local companies. |
Year(s) Of Engagement Activity | 2012,2013,2014,2015 |
URL | http://pcwww.liv.ac.uk/~cci/2015imagingday.html |
Description | Imaging workshop September 2016 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Annual imaging workshop, focused on fundamentals in imaging and specific seminars on microscopy techniques such as super-resolution microscopy, intravital imaging, Life-time imaging. The main purpose is training and increasing awareness of the imaging capabilities in Liverpool |
Year(s) Of Engagement Activity | 2016 |
URL | http://cci.liv.ac.uk/2016imagingday.html |
Description | Liverpool Cell Imaging annual workshop |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | The Centre for Cell Imaging organised a 2 day workshop focused on light microscopy techniques, imaging probes and image analysis. 90 researchers and students attended the event mainly from Liverpool and Manchester but also from other Universities in the UK. Industrial partners were invited and attended.The second day was a focused hands-on training on image analysis. |
Year(s) Of Engagement Activity | 2018 |
URL | https://cci.liv.ac.uk/2018_workshop.html |
Description | Organisation of a workshop |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | A 2 days workshop on imaging and image analysis, attended by scientists and postgraduate students from University of Liverpool and beyond as well as by company representatives (100 attendees). |
Year(s) Of Engagement Activity | 2020 |
URL | https://cci.liv.ac.uk/2019_2020_workshop.html |
Description | Primary school visit for the Science week |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | The activity consisted in 2x2h sessions with 2 year 6 classes in a primary school in Liverpool (Mosspits Lane primary school) for the Science week 2017. The children were offered activities focusing on scales in biology, use of microscopy and building their own magnifier. |
Year(s) Of Engagement Activity | 2017 |
Description | School visit to the CCI |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Schools |
Results and Impact | 50 A-level students visited the Institute of Integrative Biology, and were given a talk about imaging in the 5 dimensions. |
Year(s) Of Engagement Activity | 2018 |
Description | workshop focused on cell imaging and image analysis |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | The Centre for Cell Imaging organised a 2 day workshop focused on light microscopy techniques and image analysis. 90 researchers and students attended the event mainly from Liverpool and Manchester but also from other Universities in the UK. Industrial partners were invited and the director of the Advanced Imaging Centre at the HHMI Janelia Research Campus, Teng-Leong Chew gave a keynote lecture and a comprehensive hands-on training session on Image Analysis. |
Year(s) Of Engagement Activity | 2017 |
URL | https://cci.liv.ac.uk/2017_workshop.html |